CA2701537A1 - Compositions pour le traitement de tumeurs par l'administration directe d'un radio-isotope - Google Patents

Compositions pour le traitement de tumeurs par l'administration directe d'un radio-isotope Download PDF

Info

Publication number
CA2701537A1
CA2701537A1 CA2701537A CA2701537A CA2701537A1 CA 2701537 A1 CA2701537 A1 CA 2701537A1 CA 2701537 A CA2701537 A CA 2701537A CA 2701537 A CA2701537 A CA 2701537A CA 2701537 A1 CA2701537 A1 CA 2701537A1
Authority
CA
Canada
Prior art keywords
radioisotope
composition
bone
administration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2701537A
Other languages
English (en)
Inventor
R. Keith Frank
Kenneth Mcmillan
Jaime Simon
H. Max Loy
Stanley D. Stearns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GABRIEL INSTITUTE Inc
IsoTherapeutics Group LLC
Original Assignee
Isotherapeutics Group Llc
R. Keith Frank
Kenneth Mcmillan
Jaime Simon
H. Max Loy
Stanley D. Stearns
Gabriel Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotherapeutics Group Llc, R. Keith Frank, Kenneth Mcmillan, Jaime Simon, H. Max Loy, Stanley D. Stearns, Gabriel Institute, Inc. filed Critical Isotherapeutics Group Llc
Publication of CA2701537A1 publication Critical patent/CA2701537A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048DTPA (diethylenetriamine tetraacetic acid)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2701537A 2007-10-05 2008-02-15 Compositions pour le traitement de tumeurs par l'administration directe d'un radio-isotope Abandoned CA2701537A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99787307P 2007-10-05 2007-10-05
US99785607P 2007-10-05 2007-10-05
US60/997,873 2007-10-05
US60/997,856 2007-10-05
PCT/US2008/002026 WO2009045230A1 (fr) 2007-10-05 2008-02-15 Compositions pour le traitement de tumeurs par l'administration directe d'un radio-isotope

Publications (1)

Publication Number Publication Date
CA2701537A1 true CA2701537A1 (fr) 2009-04-09

Family

ID=40526495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701537A Abandoned CA2701537A1 (fr) 2007-10-05 2008-02-15 Compositions pour le traitement de tumeurs par l'administration directe d'un radio-isotope

Country Status (4)

Country Link
EP (1) EP2195036A4 (fr)
JP (1) JP2010540627A (fr)
CA (1) CA2701537A1 (fr)
WO (1) WO2009045230A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008232A2 (fr) 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Ablation locoregionale interne de tissus anormaux par des radionucleides
DOP2010000279A (es) * 2009-09-18 2012-06-15 Sari Asher Llc Composiciones radiofarmaceuticas no-coloidales sin sellar y metodos para el tratamiento de tejido anormal
JP5871823B2 (ja) * 2010-03-09 2016-03-01 クリオン インコーポレイテッド 同位体特定分離及びイオン特定媒体を使用するガラス固化
GB2490317A (en) * 2011-04-19 2012-10-31 Dspi Ltd Radioactive solution undergoing in situ precipitation at a tumour site for cancer therapy
US9687574B2 (en) 2011-12-21 2017-06-27 Isotherapeutics Group Llc Radioactive compositions and methods for their therapeutic use
EP2831889B1 (fr) 2012-03-26 2018-11-21 Kurion, Inc. Régénération sélective de résines de milieux spécifiques à un isotope dans des systèmes pour séparation d'isotopes radioactifs de matières de déchets liquides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849209A (en) * 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
US4915932A (en) * 1987-10-14 1990-04-10 Australian Nuclear Science & Technology Organisation Macroaggregates for radiation synovectomy
EP1389090A2 (fr) * 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Compositions d'imagerie diagnostique, leurs methodes de synthese et utilisation
WO2004050168A2 (fr) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Produits radiopharmaceutiques et microspheres radioactives pour ablation locoregionale de tissus anormaux
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
WO2007008232A2 (fr) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Ablation locoregionale interne de tissus anormaux par des radionucleides
US20060067883A1 (en) * 2004-09-24 2006-03-30 Biosphere Medical, Inc. Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof

Also Published As

Publication number Publication date
EP2195036A4 (fr) 2011-03-09
EP2195036A1 (fr) 2010-06-16
WO2009045230A1 (fr) 2009-04-09
JP2010540627A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
ES2268888T3 (es) El uso de radio-223 para dirigirse a tejidos calcificados para paliacion del dolor y terapia de cancer oseo.
Farhanghi et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer
JP5219325B2 (ja) 骨標的錯体
US10918746B2 (en) Radioactive compositions and methods for their therapeutic use
AU2001267734A1 (en) Radiotherapy
CA2701537A1 (fr) Compositions pour le traitement de tumeurs par l'administration directe d'un radio-isotope
WO2011149844A1 (fr) Administration de radio-isotopes thérapeutiques à fortes doses à un os
US20120251442A1 (en) Methods for Treatment of Tumors by Direct Administration of a Radioisotope
US20090252675A1 (en) Radionuclide Therapy for Urinary Bladder Cancer
US8709380B1 (en) Targeting agents for enhancing radiation therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150317